Price to Operating Profit (P/OP)
since 2019
Calculation
Shockwave Medical Inc., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Income (loss) from operations1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2024 | 61.09 | = | 259.89 | ÷ | 4.25 | 4.25 | = | 159,093 | ÷ | 37,396,816 | |
| Feb 27, 2023 | 55.72 | = | 189.52 | ÷ | 3.40 | 3.40 | = | 124,134 | ÷ | 36,495,387 | |
| Feb 25, 2022 | — | = | 175.59 | ÷ | -0.02 | -0.02 | = | -871 | ÷ | 35,653,563 | |
| Feb 26, 2021 | — | = | 116.76 | ÷ | -1.88 | -1.88 | = | -65,663 | ÷ | 34,842,744 | |
| Mar 12, 2020 | — | = | 29.00 | ÷ | -1.63 | -1.63 | = | -51,839 | ÷ | 31,765,657 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Shockwave Medical Inc. Annual Report.
- Share Price
- The share price exhibited a significant upward trend over the five-year period. Starting from $29 in March 2020, it increased sharply to $116.76 by February 2021. This positive momentum continued with a steady rise to $175.59 in February 2022, followed by $189.52 in February 2023. The price reached its highest level at $259.89 by February 2024, indicating strong market confidence and possibly robust company performance or growth expectations.
- Operating Profit Per Share
- Operating profit per share showed a marked improvement over the period analyzed. Initially negative at -$1.63 in March 2020, it deteriorated slightly to -$1.88 in February 2021. However, there was a substantial turnaround by February 2022 when the operating loss nearly eliminated to -$0.02, suggesting progress toward profitability. Subsequently, the company achieved positive operating profit per share values, reaching $3.40 in February 2023 and further improving to $4.25 in February 2024. This trend reflects effective operational management and increased earnings generation capacity.
- Price to Operating Profit (P/OP) Ratio
- The P/OP ratio was reported only for the last two years, where it stood at 55.72 in February 2023 and increased to 61.09 in February 2024. Although high, the increase in this ratio suggests that the market continued to value the company's operating profit at a premium, possibly due to anticipated future growth or strong competitive positioning despite the rising valuation multiples.
Comparison to Competitors
Shockwave Medical Inc., P/OP, long-term trends, comparison to competitors
| Shockwave Medical Inc. | Abbott Laboratories | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | |
|---|---|---|---|---|---|
| Feb 26, 2024 | 61.09 | 30.54 | 75.42 | 21.20 | 14.20 |
| Feb 27, 2023 | 55.72 | 22.18 | 54.49 | 20.48 | 15.89 |
| Feb 25, 2022 | — | 24.45 | 56.11 | 37.44 | 18.77 |
| Feb 26, 2021 | — | 40.69 | 88.37 | 26.29 | 14.12 |
| Mar 12, 2020 | — | 34.03 | 48.89 | 21.26 | 14.40 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).